A first-in-human Phase 1 study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies

Michal Kwiatek; Guru Subramanian Guru Murthy; Marc Hoffmann; Benoit Tessoulin; Alexey Danilov; Alvaro J. Alencar; Nirav N. Shah; Hervé Ghesquieres; Steven Le Gouill; Wojciech Jurczak; Hongmei Han; Eunice Yuen; Vishalkumar Patel; Yingying Guo-Avrutin; James M. Pauff; Lindsey E. Roeker

doi:10.1016/j.clml.2025.01.018

Back

A first-in-human Phase 1 study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies

Journal article

Peer reviewed

A first-in-human Phase 1 study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies

Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Benoit Tessoulin, Alexey Danilov, Alvaro J. Alencar, Nirav N. Shah, Hervé Ghesquieres, Steven Le Gouill, Wojciech Jurczak, …

Clinical lymphoma, myeloma and leukemia

2025-01

DOI: https://doi.org/10.1016/j.clml.2025.01.018

Appears in Miller School of Medicine - Latest Publications

Metrics

3 Record Views

Details

Title: A first-in-human Phase 1 study of LOXO-338, an oral selective Bcl-2 inhibitor, in patients with advanced hematologic malignancies
Creators: Michal Kwiatek
Guru Subramanian Guru Murthy
Marc Hoffmann
Benoit Tessoulin
Alexey Danilov
Alvaro J. Alencar
Nirav N. Shah
Hervé Ghesquieres
Steven Le Gouill
Wojciech Jurczak
Hongmei Han
Eunice Yuen
Vishalkumar Patel
Yingying Guo-Avrutin
James M. Pauff
Lindsey E. Roeker
Publication Details: Clinical lymphoma, myeloma and leukemia
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032552501502976